Sustained API price weakness
API prices have declined 10-12% over the last 12 months and continue to slide, impacting CDMO revenue growth and margins.
high · management_commentaryAkums Drugs and Pharmaceuticals Limited — Q1 FY26
Akums Drugs reported a mixed Q1 FY26.
neutral
medium
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Slow ramp-up in European exports
European dossier approvals and commercial supplies are still in early stages; achieving $100 million export target in 5 years may be delayed if regulatory or market access hurdles arise.
medium · analyst_questionTrade generic and API losses persist
Trade generic segment posted negative EBITDA of ₹5 crore, and API business reported a loss of ₹6 crore. Management is rationalizing but turnaround timeline is uncertain.
medium · data_observationGLP-1 opportunity not being pursued
Management confirmed they are not targeting semaglutide, citing limited CDMO addressable market as most players do it in-house. This could mean missing a large growth opportunity.
low · analyst_question